[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620610":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":49,"centralContacts":53,"locations":61,"responsibleParty":144,"collaborators":146,"id":150,"slug":28,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":28,"eligibilityCriteria":155,"healthyVolunteers":151,"sex":156,"minAge":157,"maxAge":28,"enrollmentInfo":158,"targetDuration":28,"studyType":161,"phases":162,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"An intermediate dose (medium dose) of PTCY, tacrolimus, MMF, and the drug ruxolitinib","EXPERIMENTAL","will receive an intermediate (medium) dose of PTCY, tacrolimus, MMF,and ruxolitinib",[13,14,15,16],"Drug: Cyclophosphamide","Drug: Mycophenolate Mofetil","Drug: Ruxolitinib","Drug: Tacrolimus",{"label":18,"type":19,"description":20,"interventionNames":21},"A full dose of PTCY, tacrolimus, and MMF (the standard GVHD prevention approach)","ACTIVE_COMPARATOR","will receive a full dose of PTCY, tacrolimus, and MMF (the standard GVHD prevention approach)",[13,14,16],[23,29,32,38,42,46],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Cyclophosphamide","An intermediate dose (medium dose) of Post-transplant Cyclophosphamide",[9],null,{"type":24,"name":25,"description":30,"armGroupLabels":31,"otherNames":28},"A full dose of Post-transplant Cyclophosphamide",[18],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Mycophenolate Mofetil","Day +5 to +35",[18,9],[37],"MMF",{"type":24,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Ruxolitinib","twice a day",[9],{"type":24,"name":43,"description":44,"armGroupLabels":45,"otherNames":28},"Tacrolimus","Day +5, taper per SoC",[18],{"type":24,"name":43,"description":47,"armGroupLabels":48,"otherNames":28},"Day +5, taper initiation within 2 weeks of starting Ruxolitinib",[9],[50],{"name":51,"affiliation":5,"role":52},"Doris Ponce, MD, MS","PRINCIPAL_INVESTIGATOR",[54,58],{"name":51,"role":55,"phone":56,"phoneExt":28,"email":57},"CONTACT","646-608-3739","BMTTrials@mskcc.org",{"name":59,"role":55,"phone":60,"phoneExt":28,"email":28},"Brian Shaffer, MD","646-608-3737",[62,78,89,100,112,123,133],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States",{"type":70,"coordinates":71},"Point",[72,73],-74.54932,40.70621,{"lat":73,"lon":72},[76],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},"Doris Ponce, MD",{"facility":79,"status":64,"city":80,"state":66,"zip":81,"country":68,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":70,"coordinates":83},[84,85],-74.11709,40.39428,{"lat":85,"lon":84},[88],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":90,"status":64,"city":91,"state":66,"zip":92,"country":68,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":70,"coordinates":94},[95,96],-74.02292,41.04676,{"lat":96,"lon":95},[99],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":101,"status":64,"city":102,"state":103,"zip":104,"country":68,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":70,"coordinates":106},[107,108],-73.29289,40.84288,{"lat":108,"lon":107},[111],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":113,"status":64,"city":114,"state":103,"zip":115,"country":68,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":70,"coordinates":117},[118,119],-73.71263,40.96899,{"lat":119,"lon":118},[122],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":124,"status":64,"city":103,"state":103,"zip":125,"country":68,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",{"type":70,"coordinates":127},[128,129],-74.00597,40.71427,{"lat":129,"lon":128},[132],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"facility":134,"status":64,"city":135,"state":103,"zip":136,"country":68,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Memorial Sloan Kettering Nassau (Limited Protocol Activites)","Rockville Centre","11553",{"type":70,"coordinates":138},[139,140],-73.64124,40.65871,{"lat":140,"lon":139},[143],{"name":77,"role":55,"phone":56,"phoneExt":28,"email":28},{"type":145,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[147],{"name":148,"class":149},"Incyte Corporation","INDUSTRY","100620610",false,"NCT07359859","A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY","Inclusion Criteria:\n\n* Patients ≥18- years-old at time of consent\n* Diagnosis: hematologic malignancy in morphologic remission (blasts \\\u003C5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed. Patients with lymphoma must have a complete or partial response\n* Donor: related or unrelated 7-8\u002F8 HLA-matched or related haploidentical\n* Karnofsky score ≥ 70%\n* Female subjects of childbearing potential (\\\u003C50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.\n\n  °Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of the study drug. Effective birth control includes: \\*Intrauterine device (IUD) plus one barrier method \\*Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method \\*2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \\* A vasectomized partner.\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug\n\nExclusion Criteria:\n\n* Recipient of CD34+ selected or engineered stem cell graft\n* Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin)\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ\n* Severely impaired renal function defined by serum creatinine \\> 2mg\u002FdL, renal dialysis requirement.\n* Use of investigational agent within 14 days pre-HCT\n* Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months\n* Uncontrolled psychiatric illness\n* Female patient who is pregnant or breastfeeding\n* Known allergy or sensitivity to ruxolitinib","ALL","18 Years",{"count":159,"type":160},40,"ESTIMATED","INTERVENTIONAL",[163],"PHASE2","The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).",[166],"Hematologic Malignancies",[168,169],"graft-versus-host disease (GVHD)","allogeneic hematopoietic stem cell transplant (allo-HCT)","2026-05-26",{"date":172,"type":173},"2026-05-27","ACTUAL",{"date":175,"type":173},"2026-01-20",{"date":177,"type":160},"2029-01",{"name":5,"class":6},7]